Status:
RECRUITING
Effect of Dexmedetomidine on Postoperative Delirium After Awake Craniotomies
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Dexmedetomidine
Delirium
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Postoperative delirium (POD) is a common complication, and the incidence of POD ranges from 10% to 60%. Previous studies suggested that frontal approach and tumor located at the temporal lobe were ind...
Eligibility Criteria
Inclusion
- Patients undergoing selective awake craniotomies.
- Age ≥18 years.
- Obtain written informed consent.
Exclusion
- Preoperative moderate and severe cognitive impairment (Montreal Cognitive Assessment, MoCA\< 18).
- Preoperative psychotropic medication within one year.
- BMI≤18 or ≥30 Kg/ m2
- Pregnant or lactating women.
- History of traumatic brain injury or neurosurgery.
- Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block.
- Severe hepatic or renal dysfunction.
Key Trial Info
Start Date :
March 31 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT05195034
Start Date
March 31 2022
End Date
December 31 2025
Last Update
February 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Tian Tan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100160